The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment |
| |
Authors: | Skinner-Adams Tina S Butterworth Alice S Porter Kimberly A D'Amico Ronald Sawe Fred Shaffer Doug Siika Abraham Hosseinipour Mina C Stringer Elizabeth Currier Judith S Chipato Tsungai Salata Robert Lockman Shahin Eron Joseph J Meshnick Steven R McCarthy James S |
| |
Institution: | Infectious Diseases Division, Queensland Institute of Medical Research, Brisbane, Queensland, Australia. tinaS@qimr.edu.au |
| |
Abstract: | HIV protease inhibitors (PIs) show antimalarial activity in vitro and in animals. Whether this translates into a clinical benefit in HIV-infected patients residing in malaria-endemic regions is unknown. We studied the incidence of malaria, as defined by blood smear positivity or a positive Plasmodium falciparum histidine-rich protein 2 antigen test, among 444 HIV-infected women initiating antiretroviral treatment (ART) in the OCTANE trial (A5208; ClinicalTrials.gov: NCT00089505). Participants were randomized to treatment with PI-containing vs. PI-sparing ART, and were followed prospectively for ≥48 weeks; 73% also received cotrimoxazole prophylaxis. PI-containing treatment was not associated with protection against malaria in this study population. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|